214 related articles for article (PubMed ID: 7544963)
1. [Limitation of clinical usefulness of tumor marker].
Ishii M
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1139-45. PubMed ID: 7544963
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
3. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
6. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in cancer of the digestive system].
Zinser JW
Rev Gastroenterol Mex; 1997; 62(3):145-8. PubMed ID: 9480520
[TBL] [Abstract][Full Text] [Related]
8. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
[TBL] [Abstract][Full Text] [Related]
9. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma.
Lopez JB; Balasegaram M; Timor J; Thambyrajah V
Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242
[TBL] [Abstract][Full Text] [Related]
10. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
11. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
12. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
13. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
15. [Sense and nonsense of tumor markers in practice].
Joss R; Cerny T
Schweiz Med Wochenschr; 1990 May; 120(19):693-703. PubMed ID: 1693445
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
17. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
Chang IH; Ahn SH; Han JH; Kim TH; Kim YS; Myung SC
J Urol; 2009 Feb; 181(2):567-72; discussion 572-3. PubMed ID: 19084848
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
von Kleist S; Hesse Y; Kananeeh H
Anticancer Res; 1996; 16(4B):2325-31. PubMed ID: 8694564
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]